PMC5892301_01
Hematoxylin-eosin staining of the liver biopsy showing canalicular cholestasis predominantly in the centrizonal areas with no obvious hepatocyte injury. (a) Magnification x10. (b) Magnification x20.
CRIONM2018-1809432.001.jpg
PMC5892301_01_CRIONM2018-1809432.001.jpg
fig1
Biopsy of the patient's liver showed cholestasis, mild portal chronic, and minimal lobular inflammation (Figures 1(a) and 1(b)).
MRI of the patient's abdomen and pelvis showing resolution of paraaortic and iliac lymphadenopathy after ADT and docetaxel treatment. (a) Paraaortic lymphadenopathy (shown by white arrows) before treatment. (b) Resolution of paraaortic lymphadenopathy after treatment. (c) Left iliac lymphadenopathy (shown by white arrow) before treatment. (d) Resolution of left iliac lymphadenopathy after treatment.
CRIONM2018-1809432.002.jpg
PMC5892301_01_CRIONM2018-1809432.002.jpg
fig2
Magnetic resonance imaging (MRI) of the patient's abdomen revealed bulky, diffuse lymphadenopathy and secondary lymphomatous involvement of the prostate gland (Figures 2(a) and 2(b)). The patient's most recent staging imaging after completion of chemotherapy revealed excellent response with resolution of retroperitoneal and pelvic lymphadenopathy with decreased enhancement of multiple bone lesions (Figures 2(c) and 2(d)).
Trend in PSA and total bilirubin levels after diagnosis. Solid arrow represents the time of initiation of androgen deprivation therapy, and dotted arrow represents the time of initiation of docetaxel.
CRIONM2018-1809432.003.jpg
PMC5892301_01_CRIONM2018-1809432.003.jpg
fig3
Within 2 months of initiating ADT, his PSA level declined to 6.5 ng/mL (Figure 3).